Results · Apr-Jun 2026 · filed 11 Aug 2026
Camlin Fine Sciences Q1 FY27 results
Sales grew 23% to ₹520 crore from ₹424 crore in Apr-Jun 2025.
Operating profit fell 51% to ₹9.3 crore, an operating margin of 1.8% (down 2.7 points from a year ago).
The net loss widened to ₹33.6 crore from ₹10.7 crore.
Against Jan-Mar 2026: sales +22%, swings to a loss.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 519.9 | 423.6 | +23% |
| Operating profit (EBITDA) | 9.3 | 19.0 | −51% |
| Operating margin | 1.8% | 4.5% | −2.7 pts |
| Net profit | -33.6 | -10.7 | loss widens |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 17 Aug 2026Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- 12 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 11 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 11 Aug 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 11 Aug 2026Board Meeting Outcome for Outcome Of Board Meeting Dated August 11, 2026
- 11 Aug 2026Un-Audited Financial Results For The Quarter Ended June 30, 2026
- 11 Aug 2026Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- 11 Aug 2026Shareholder Meeting / Postal Ballot-Outcome of AGM
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.